Acetyl Hexapeptide-8
Also referenced as: Argireline
A cosmetic peptide derived from a protein involved in neurotransmitter release.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Not FDA Approved
A cosmetic ingredient, not an FDA-approved anti-aging drug. Cosmetic marketing and ingredient safety reviews do not establish injectable safety or therapeutic approval.
- Human data
- Limited
No registered clinical trials identified
- Last reviewed
- October 27, 2026
Overview
A cosmetic peptide derived from a protein involved in neurotransmitter release.
A cosmetic ingredient, not an FDA-approved anti-aging drug. Cosmetic marketing and ingredient safety reviews do not establish injectable safety or therapeutic approval.
Moisturizer-level wrinkle findings are not evidence of medical muscle paralysis.
Why It's Being Studied
- Wrinkle appearance
- Topical delivery
Mechanism of Action
It is designed to interfere with SNAP-25-related signalling in laboratory systems; penetration through intact skin is a separate question.
It is designed to interfere with SNAP-25-related signalling in laboratory systems; penetration through intact skin is a separate question. Moisturizer-level wrinkle findings are not evidence of medical muscle paralysis.
Skin remodelling and the hair cycle
Tap each stage to see what happens.
Background: Skin & Hair Research
Skin and hair research looks at collagen synthesis, wound closure, pigmentation and the hair-follicle cycle.
Topical cosmetic research is often industry-funded and small. Injected use of cosmetic peptides has little human data.
Research Areas & Routes Studied
- Wrinkle appearance
- Topical delivery
- Topical cosmetic formulations
Evidence Summary
Small, short-term cosmetic studies exist, but they do not establish effects equivalent to injected botulinum toxin.
Higher tiers carry more weight. Filled tiers have evidence for Acetyl Hexapeptide-8; tap to read it.
- Small, short-term cosmetic studies exist, but they do not establish effects equivalent to injected botulinum toxin.
3 cited sources.
- Clinical trial1
- Narrative review1
- Regulatory document1
Human clinical evidence
- Small, short-term cosmetic studies exist, but they do not establish effects equivalent to injected botulinum toxin.
Reported Adverse Events in Research
- Topical irritation and sensitivity depend on the formulation; injectable safety is not established.
Limitations of Current Evidence
- Moisturizer-level wrinkle findings are not evidence of medical muscle paralysis.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Was the product topical or injected?
- Were results measured by instruments or by photos and self-assessment?
- Who funded the study?
- Cosmetic claims face a lower evidence bar than medical claims.
- Pigmentation-affecting compounds carry documented risks, including changes in moles.
- Anagen
- The active growth phase of a hair follicle.
- Dermis
- The skin layer beneath the surface that holds collagen.
- Melanocortin
- A hormone family that affects pigmentation and appetite.
Compare With Other Compounds
| Acetyl Hexapeptide-8 | GHK-Cu | |
|---|---|---|
| Evidence grade | C — Early Human Research | C — Early Human Research |
| Regulatory status | Not FDA Approved | Not FDA Approved |
| Human data | Limited | Limited |
| Clinical trials | None identified | None identified |
| Research routes | Topical cosmetic formulations | Topical, Intradermal (cosmetic research) |
| Cited sources | 3 | 2 |
Frequently Asked Questions
Research References
- Clinical trial
Acetyl Hexapeptide-8 — published research
- Narrative review
Cosmetic peptide research and delivery limitations
- Regulatory document
FDA: cosmetics are not preapproved medicines